An Update on Anticoagulation in Atrial Fibrillation

John Amerena1, Daryl Ridley2

  • 1Deakin University, Geelong, Vic, Australia.

Insights

Direct-acting oral anticoagulants (DOACs) offer a new approach to preventing strokes in atrial fibrillation (AF) patients. DOACs are expected to become the primary stroke prevention therapy for non-valvular AF.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) increases stroke risk, necessitating anticoagulation.
  • Warfarin was the standard anticoagulant for stroke prevention in AF.
  • Novel direct-acting oral anticoagulants (DOACs) have emerged as alternatives.

Purpose of the Study:

  • To discuss the paradigm shift in anticoagulation therapy for AF.
  • To highlight the role of DOACs in stroke prevention.
  • To guide physicians on current anticoagulation strategies for AF.

Main Methods:

  • Review of current anticoagulation guidelines and clinical evidence.
  • Comparison of warfarin with DOACs for stroke prevention in AF.
  • Analysis of treatment philosophy changes in AF management.

Main Results:

  • DOACs represent a significant advancement in stroke prevention for AF.
  • The focus of treatment decisions is shifting from 'when to use' to 'when not to use' anticoagulation.
  • Warfarin remains relevant for specific patient subgroups.

Conclusions:

  • DOACs are poised to become the predominant therapy for stroke prevention in non-valvular AF.
  • Physicians must adapt to new treatment algorithms considering DOACs.
  • Anticoagulation management in AF has entered a new era with DOAC availability.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
410
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K